Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder

benzinga.com/news/fda/25/09/47688060/adial-pharmaceuticals-highlights-favorable-comments-from-fda

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Tuesday received the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held in July.
The minutes provide the FDA's formal input into the AD04 Phase 3 adaptive clinical trial design…

This story appeared on benzinga.com, 2025-09-16 12:03:43.
The Entire Business World on a Single Page. Free to Use →